Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity

On April 23, Mizuho reiterated an Outperform standing connected Revolution Medicines Inc. shares (NASDAQ:RVMD) and raised the terms people to $185 from $140.

The terms people hike comes amid increasing assurance astir the company’s pb campaigner drug, daraxonrasib, successful the attraction of pancreatic cancer. The probe steadfast has already accrued the drug’s occurrence probability to 90% from 80%, buoyed by caller objective proceedings data. It has besides accelerated the drug’s adoption trajectory arsenic a first- and second-line attraction for pancreatic cancer.

Immediate first-line information showed landmark analyses astatine 6 months for the daraxonrasib regimen that were comparable to those of gemcitabine positive nab-paclitaxel. Mizuho remains optimistic astir the ongoing RaSolute 303 survey pursuing daraxonrasib’s show arsenic a second-line treatment. It expects the cause to make $14 cardinal successful risk-adjusted pancreatic crab revenues by 2035.

Revolution Medicines Inc. (NASDAQ:RVMD) is simply a clinical-stage oncology company. It develops targeted therapies for patients with RAS-addicted cancers, which thrust astir 30% of quality cancers. The institution uses a proprietary tri-complex inhibitor level to people progressive RAS proteins (RAS-ON inhibitors).

While we admit the imaginable of RVMD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy successful 2026.

Disclosure: None. Follow Insider Monkey connected Google News.